Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT-TN-IV: Sacituzumab Govitecan + Pembrolizumab vs SoC in Early TNBC
NCT07178730Phase 3Not yet recruiting
- Sponsor
- Women's Cancer Study Group
- Start
- Aug 2026
- Primary completion
- Mar 2033
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacituzumab govitecan in triple-negative breast cancer (TNBC), sponsored by Women's Cancer Study Group. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07178730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07178730.